Valeant Pharmaceuticals Agrees to Delay Efinconazole Launch

Valeant Pharmaceuticals International, Inc. VRX announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not occur until after the September 2013 arbitration hearing to resolve the breach of contract dispute with Anacor Pharmaceuticals ANAC. As a result, the preliminary injunction hearing which was scheduled for May 6-8, 2013 has been canceled. Valeant intends to vigorously contest Anacor's claims and continues to expect to launch the product in 2013. About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com. Forward-looking Statements This press release may contain forward-looking statements, including, but not limited to, statements regarding our expectation with respect to the FDA response and our launch plans with respect to efinaconazole.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions. These statements are See full press release